Hepcludex (bulevirtide-gmod)
Gilead Sciences (GILD)
ApprovedMay 22, 2026
Marketer take
The first US-approved treatment for chronic hepatitis delta, so hepatologists will need help with HDV testing and diagnosis among hepatitis B patients, where it is often missed.
- Sponsor company
- Gilead Sciences (GILD)
- Indication
- To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Therapeutic area
- Infectious disease, Hepatology
- Event
- FDA approval
- Date
- May 22, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?